


AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions and listings of the claims in this application.

Listing of the Claims:

Claims 1-80 (Canceled)

81. (Currently Amended) A compound ~~according to claim 80~~ having the Formula (2)




Formula (2)

wherein

R¹ is selected from the group consisting of H, C₁-C₆ alkyl and acyl;

BAZL is selected from the group consisting of



~~L is a single bond or is a C₁-C₅ hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -O-, -S-, -S(O)- and -S(O)₂- and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C₁-C₄ alkyl;~~

~~_____ Z is selected from the group consisting of a single bond, N(R⁺), O, S, S(O) and S(O)₂;~~

~~_____ A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;~~

~~———B is selected from the group consisting of a single bond, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, optionally substituted alkylheteroarylene, optionally substituted C₄-C₂ alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene and optionally substituted $-(CH_2)_m-C(O)-N(R^4)-(CH_2)_n-$, wherein n is an integer from 0 to 6, m is an integer from 0 to 6;~~

M is selected from the group consisting of O, S, NH, NR⁴, NOH and NOR⁴;

R² is selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR⁴, CONHR⁴, NHCOR⁴, NHCOOR⁴, NHCONHR⁴, C(=NOH)R⁴, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR⁴ and acyl; each of which may optionally be substituted,

or

~~———R² together with the nitrogen to which it is attached and a portion of B form an optionally substituted heterocycloalkyl group;~~

R³ is independently selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl,

alkenyloxy, alkynyloxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR^4 , CONHR^4 , NHCOR^4 , NHCOOR^4 , NHCONHR^4 , C(=NOH)R^4 , alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR^4 and acyl; each of which may optionally be substituted;


Q is selected from the group consisting of $-\text{S(O)}_2-$, $-\text{C(=O)}-$ and $-\text{C(=S)}-$;

G is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl;

each R^4 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl; each of which may be optionally substituted;

or a pharmaceutically acceptable salt or prodrug thereof.

82. (Currently Amended) A compound according to claim 81 having the Formula (2a)



Formula (2a)

wherein

——— R^1 is selected from the group consisting of H, C_1 - C_6 alkyl and acyl;

——— L is a single bond or is a C_1 - C_5 hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -O-, -S-, -S(O)- and -S(O)₂- and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C_1 - C_4 alkyl;

——— Z is selected from the group consisting of a single bond, $N(R^1)$, O, S, S(O) and S(O)₂;

——— A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;

——— B is selected from the group consisting of a single bond, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, optionally substituted alkylheteroarylene, optionally substituted C_1 - C_3 alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene optionally substituted heterocycloalkylene and optionally substituted $-(CH_2)_m-C(O)-N(R^4)-(CH_2)_n-$, wherein n is an integer from 0 to 6, m is an integer from 0 to 6;

——— M is selected from the group consisting of O, S, NH, NR^4 , NOH and NOR^4 ;

wherein

R^2 is selected from the group consisting of H, C_1 - C_{10} alkyl, alkenyl, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C_4 - C_9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino,

phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, $-\text{C}(\text{O})\text{OR}^4$, $-\text{CONHR}^4$, $-\text{NHCONHR}^4$, $\text{C}(=\text{NOH})\text{R}^4$, and acyl;

R^3 is selected from the group consisting of H, C_1 - C_{10} alkyl, alkenyl, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C_4 - C_9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, $-\text{C}(\text{O})\text{OR}^4$, $-\text{CONHR}^4$, $-\text{NHCONHR}^4$, $\text{C}(=\text{NOH})\text{R}^4$, and acyl;

Q is selected from the group consisting of $-\text{S}(\text{O})_2-$, $-\text{CO}-$ and $-\text{C}(=\text{S})-$;

G is selected from optionally substituted aryl, optionally substituted heteroaryl, alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl, wherein the substituents are independently selected from the group consisting of X, Y, R^4 , hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, $-\text{C}(\text{O})\text{OR}^4$, $-\text{C}(\text{O})\text{OH}$, $-\text{SH}$, $-\text{CONHR}^4$, $-\text{NHCONHR}^4$, and $\text{C}(=\text{NOH})\text{R}^4$;

R^4 is selected from the group consisting of C_1 - C_4 alkyl, heteroalkyl, aryl, heteroaryl and acyl;

X and Y are the same or different and are independently selected from the group consisting of H, halo, C_1 - C_4 alkyl, NO_2 , OR^4 , SR^4 , $\text{C}(\text{O})\text{R}^5$, and NR^6R^7 ;

R^5 is C_1 - C_4 alkyl;

R^6 and R^7 are the same or different and are independently selected from the group consisting of H, C₁-C₆ alkyl, C₄-C₉ cycloalkyl, C₄-C₉ heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroaryl alkyl.

or a pharmaceutically acceptable salt or prodrug thereof.

Claims 83-96 (Cancelled).

97. (Currently Amended) A compound according to claim 81 wherein the group BAZL is a group of formula $-(CH_2)_n-$ wherein n is an integer from $[[1]]$ 3 to 7.

98. (Currently Amended) A compound according to claim 81 wherein the group BAZL is a group of formula $-(CH_2)-$ phenyl-.

Claims 99-101 (Cancelled).

102. (Previously Presented) A compound according to claim 81 wherein $R^1 = H$.

103. (Previously Presented) A compound according to claim 81 wherein M is O.

104. (Previously Presented) A compound according to claim 81 wherein M is S.

105. (Previously Presented) A compound according to claim 81 wherein Q is S(O)₂.

106. (Previously Presented) A compound according to claim 81 wherein Q is CO.

107. (Previously Presented) A compound according to claim 81 wherein G is optionally substituted aryl.

108. (Previously Presented) A compound according to claim 81 wherein G is phenyl.

109. (Previously Presented) A compound according to claim 81 wherein G is 4-methylphenyl.

110. (Previously Presented) A compound according to claim 81 wherein R² is selected from the group consisting of H, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted arylheteroalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylheteroalkyl, optionally substituted cycloalkylalkyl and optionally substituted heterocycloalkylalkyl.

111. (Previously Presented) A compound according to claim 81 wherein R² is selected from the group consisting of H, 2-(1H-indol-3-yl)-ethyl, 2-(2-methyl-1H-indol-3-yl)-ethyl, pyridin-3-ylmethyl, 3-hydroxy-propyl, 2-pyridin-2-yl-ethyl, 2-pyridin-3-yl-ethyl, pyridin-3-ylmethyl, 2-pyridin-4-yl-ethyl, benzyl, 3-phenyl-propyl, 2-phenoxy-ethyl, morpholin-4-yl, pyridin-2-yl, phenethyl, 2-(4-bromo-phenyl)-ethyl, 2-(4-fluoro-phenyl)-ethyl, 3-imidazol-1-yl-propyl, 2-(1H-imidazol-4-yl)-ethyl, 1H-Benzoimidazol-2-ylmethyl, 2-piperidin-1-yl-ethyl, 2-pyrrolidin-1-yl-ethyl, 2-cyclohex-1-enyl-ethyl, 2-ethyl-hexyl, 2-thiophen-2-yl-ethyl, 3,3-diphenyl-propyl, 2-biphenyl-4-yl-ethyl, 2-(4-phenoxy-phenyl)-ethyl, 2-(3-phenoxy-phenyl)-ethyl, 2-(2,3-dimethoxy-phenyl)-ethyl, 2-(2,4-dichloro-phenyl)-ethyl, cyclohexylmethyl, hexyl, isobutyl, 3-isopropoxy-propyl, 2-phenoxy-ethyl, 2-isopropoxy-ethyl, 3-methoxy-benzyl, 4-[1,2,3]thiadiazol-4-yl-benzyl, 2,4-dichloro-benzyl, 2-(2-methoxy-phenyl)-ethyl, 2-(3-fluoro-phenyl)-ethyl, 2-(2-fluoro-phenyl)-ethyl, 2,2-diphenyl-ethyl, 2-(4-methoxy-phenyl)-ethyl, 2-(3-chloro-phenyl)-ethyl, 4-phenyl-butyl, 3-phenyl-propyl, 3,3-diphenyl-propyl, 3-(4-methyl-piperazin-1-yl), 3-morpholin-4-yl-propyl, 3-(2-oxo-pyrrolidin-1-yl)-propyl, 3-pyrrolidin-1-yl-propyl, tetrahydro-furan-2-ylmethyl, 1,5-dimethyl-hexyl, 2-diethylamino-ethyl and 2-dimethylamino-ethyl.

112. (Previously Presented) A compound according to claim 81 wherein R² is selected from the group consisting of H, 2-(1H-indol-3-yl)-ethyl, 2-(2-methyl-1H-indol-3-yl)-ethyl,


pyridin-3-ylmethyl, 3-hydroxy-propyl, 2-pyridin-2-yl-ethyl, 2-pyridin-3-yl-ethyl, pyridin-2-ylmethyl, pyridin-3-ylmethyl, 2-pyridin-4-yl-ethyl, benzyl, 3-phenyl-propyl, 2-phenoxy-ethyl, 2-morpholino ethyl, 2-phenyl ethyl, 2-(4-bromo-phenyl)-ethyl, 2-(4-fluoro-phenyl)-ethyl, 3-imidazol-1-yl-propyl, 2-(1H-imidazol-4-yl)-ethyl, 1H-Benzoimidazol-2-ylmethyl, 2-piperidin-1-yl-ethyl and 2-pyrrolidin-1-yl-ethyl.

113. (Previously Presented) A compound according to claim 81 wherein R² is selected from the group consisting of H, 2-(1H-indol-3-yl)-ethyl, 2-(2-methyl-1H-indol-3-yl)-ethyl, 2-phenyl ethyl, 2-piperidin-1-yl-ethyl and 2-pyrrolidin-1-yl-ethyl.


114. (Previously Presented) A compound according to claim 81 wherein the optional substituents are selected from the group consisting of halogen, =O, =S, -CN, -NO₂, -CF₃, -OCF₃, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkenyl, heterocycloalkylalkenyl, arylalkenyl, heteroarylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, arylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycycloalkyl, alkoxyheterocycloalkyl, alkoxyaryl, alkoxyheteroaryl, alkoxy-carbonyl, alkylaminocarbonyl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, phenoxy, benzyloxy, heteroaryloxy, arylalkyloxy, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, alkylsulfinyl, arylsulfinyl, aminosulfinylaminoalkyl, -COOH, -COR⁵, -C(O)OR⁵, CONHR⁵, NHCOR⁵, NHCOOR⁵, NHCONHR⁵, C(=NOH)R⁵, -SH, -SR⁵, -OR⁵ and acyl,

wherein each R⁵ is independently selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted.


115. (Currently Amended) A compound according to claim [[80]] 81 selected from the group consisting of




8-[3-(4-methylbenzenesulfonyl)-ureido]-octanoic acid hydroxyamide,




7-[3-(4-methylbenzenesulfonyl)-ureido]-heptanoic acid hydroxyamide,




6-[3-(4-methylbenzenesulfonyl)-ureido]-hexanoic acid hydroxyamide,




6-[3-(benzenesulfonyl)-ureido]-hexanoic acid hydroxyamide,




N-Hydroxy-4-[3-(4-methylbenzenesulfonyl)ureido]methylbenzamide,




N-Hydroxy-2-{4-[3-(4-methylbenzenesulfonyl)ureido]-phenyl}-acetamide,




N-Hydroxy-2-{3-[3-(4-methylbenzenesulfonyl)ureido]-phenyl}-acetamide,




N-Hydroxy-3-{4-[3-(4-methylbenzenesulfonyl)ureido]-phenyl}-acrylamide,




N-Hydroxy-3-{3-[3-(4-methylbenzenesulfonyl)ureido]-phenyl}-acrylamide,




6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide,




7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide,




8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide,




6-[3-Benzoyl-1-(3-phenyl-propyl)-ureido]-hexanoic acid hydroxyamide,




4-(3-Benzoyl-ureidomethyl)-N-hydroxy-benzamide,




2-[4-(3-Benzoyl-ureido)-phenyl]-N-hydroxy-acetamide,




2-[3-(3-Benzoyl-ureido)-phenyl]-N-hydroxy-acetamide,




3-[4-(3-Benzoyl-ureido)-phenyl]-N-hydroxy-acrylamide,




3-(4-{3-Benzoyl-1-[2-(1H-indol-3-yl)-ethyl]-ureidomethyl}-phenyl)-N-hydroxy-acrylamide,




3-[4-(3-Benzoyl-1-pyridin-3-ylmethyl-ureidomethyl)-phenyl]-N-hydroxy-acrylamide,




3-{4-[3-Benzoyl-1-(3-hydroxy-propyl)-ureidomethyl]-phenyl}-N-hydroxy-acrylamide,




4-{3-Benzoyl-1-[2-(1H-indol-3-yl)-ethyl]-ureidomethyl}-N-hydroxy-benzamide,




4-(3-Benzoyl-ureido)-N-hydroxy-butyramide,




4-(3-Benzoyl-1-benzyl-ureidomethyl)-N-hydroxybenzamide,




4-[3-Benzoyl-1-(2-pyridin-2-ylethyl)-ureidomethyl]-N-hydroxybenzamide,




4-[3-Benzoyl-1-(3-hydroxypropyl)-ureidomethyl]-N-hydroxybenzamide,




3-[4-(3-Benzoyl-1-benzyl-ureidomethyl)-phenyl]-N-hydroxyacrylamide,




3-{4-[3-Benzoyl-1-(3-phenylpropyl)-ureidomethyl]-phenyl}-N-hydroxyacrylamide,




3-{4-[3-Benzoyl-1-(2-phenoxyethyl)-ureidomethyl]-phenyl}-N-hydroxyacrylamide,




4-[3-Benzoyl-1-(3-phenyl-propyl)-ureidomethyl]-N-hydroxybenzamide,




4-(3-Benzoyl-1-pyridin-3-ylmethyl-ureidomethyl)-N-hydroxybenzamide,




(S)-6-[2-(3-Benzoyl-ureido)-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid hydroxyamide,




4-(4-Benzoylamino-carbonyl-piperazin-1-ylmethyl)-N-hydroxybenzamide,




7-(3-Benzoyl-1-pyridin-2-ylmethyl-ureido)-heptanoic acid hydroxyamide,




6-(3-Benzoyl-1-pyridin-2-ylmethyl-ureido)-hexanoic acid hydroxyamide,




3-{4-[3-Benzoyl-1-(2-morpholin-4-yl-ethyl)-ureidomethyl]-phenyl}-N-hydroxy-acrylamide,




7-(3-Benzoyl-1-benzyl-ureido)-heptanoic acid hydroxyamide,




6-(3-Benzoyl-1-benzyl-ureido)-hexanoic acid hydroxyamide,




3-{4-[3-Benzoyl-1-(2-pyridin-2-yl-ethyl)-ureidomethyl]-phenyl}-N-hydroxy-acrylamide,




3-[4-(3-Benzoyl-1-phenethyl-ureidomethyl)-phenyl]-N-hydroxy-acrylamide,




3-(4-{3-Benzoyl-1-[2-(4-bromo-phenyl)-ethyl]-ureidomethyl}-phenyl)-N-hydroxy-acrylamide,




3-(4-{3-Benzoyl-1-[2-(4-fluoro-phenyl)-ethyl]-ureidomethyl}-phenyl)-N-hydroxy-acrylamide,




N-{4-[4-(2-Hydroxycarbonyl-vinyl)-benzyl]-piperazine-1-carbonyl}-benzamide,




3-{4-[3-Benzoyl-1-(3-imidazol-1-yl-propyl)-ureidomethyl]-phenyl}-N-hydroxy-acrylamide,




3-(4-{3-Benzoyl-1-[2-(1H-imidazol-4-yl)-ethyl]-ureidomethyl}-phenyl)-N-hydroxy-acrylamide,




6-(3-Benzoyl-thioureido)-hexanoic acid hydroxyamide,




3-{4-[1-(1H-Benzoimidazol-2-ylmethyl)-3-benzoyl-ureidomethyl]-phenyl}-N-hydroxy-acrylamide,




3-{4-[3-Benzoyl-1-(2-pyridin-3-ylethyl)-ureidomethyl]-phenyl}-N-hydroxy-acrylamide,



3-{4-[3-Benzoyl-1-(2-pyridin-4-ylethyl)-ureidomethyl]-phenyl}-N-hydroxy-acrylamide,




3-{4-[3-Benzoyl-1-(2-piperidin-1-ylethyl)-ureidomethyl]-phenyl}-N-hydroxy-acrylamide, and




3-{4-[3-Benzoyl-1-(2-pyrrolidin-1-ylethyl)-ureidomethyl]-phenyl}-N-hydroxy-acrylamide

or a pharmaceutically acceptable salt or prodrug thereof.


116. (Currently Amended) A compound according to claim [[80]] 81 selected from the group consisting of




6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide,




8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide,




4-(3-Benzoyl-ureidomethyl)-N-hydroxy-benzamide,




3-(4-{3-Benzoyl-1-[2-(1H-indol-3-yl)-ethyl]-ureidomethyl}-phenyl)-N-hydroxy-acrylamide,




3-[4-(3-Benzoyl-1-phenethyl-ureidomethyl)-phenyl]-N-hydroxy-acrylamide,



6-(3-Benzoyl-thioureido)-hexanoic acid hydroxyamide,



3-{4-[3-Benzoyl-1-(2-piperidin-1-yl-ethyl)-ureidomethyl]-phenyl}-N-hydroxy-acrylamide, and



3-{4-[3-Benzoyl-1-(2-pyrrolidin-1-yl-ethyl)-ureidomethyl]-phenyl}-N-hydroxy-acrylamide,

or a pharmaceutically acceptable salt or prodrug thereof.

117. (Currently Amended) A pharmaceutical composition including a compound according to claim [\[\[80\]\] 81](#) and a pharmaceutically acceptable diluent, excipient or carrier.

118. (Currently Amended) A method of treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis in a patient, the method including administration of a therapeutically effective amount of a compound according to claim [\[\[80\]\] 81](#) to the patient.

119. (Previously Presented) A method according to claim 118 wherein the disorder is a proliferative disorder.

120. (Previously Presented) A method according to claim 119 wherein the proliferative disorder is cancer.

121. (Previously Presented) A method according to claim 120 wherein the cancer is selected from breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.

122. (Currently Amended) A method of modifying deacetylase activity including contacting the deacetylase with a compound according to claim [[80]] 81.

123. (Previously Presented) A method according to claim 122 wherein the deacetylase activity is histone deacetylase activity.

124. (Previously Presented) A method according to claim 123 wherein the deacetylase activity is class I histone deacetylase activity.

125. (Previously Presented) A method according to claim 123 wherein the histone deacetylase is HDAC1.

126. (Previously Presented) A method according to claim 123 wherein the histone deacetylase is HDAC8.

127. (Currently Amended) A method of treatment of a disorder that can be treated by the inhibition of deacetylase activity in a patient including administration of a therapeutically effective amount of a compound according to claim [[80]] 81 to the patient.

128. (Previously Presented) A method according to claim 127 wherein the deacetylase activity is histone deacetylase activity.

129. (Currently Amended) A method of treatment of a disorder that is mediated by histone deacetylase activity in a patient including administration of a therapeutically effective amount of a compound according to claim [[80]] 81 to the patient.

130. (Previously Presented) A method according to claim 127 wherein the disorder is selected from the group consisting of Proliferative disorders (e.g. cancer); Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesia, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Progressive supranuclear palsy, Pick's disease, Intracerebral haemorrhage, Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration, Rubeotic glaucoma, Interstitial keratitis, Diabetic retinopathy; Inflammatory diseases and/or Immune system disorders including Rheumatoid Arthritis (RA), Osteoarthritis, Juvenile chronic arthritis, Graft versus Host disease, Psoriasis, Asthma, Spondyloarthropathy, Crohn's Disease, Inflammatory bowel disease, Colitis Ulcerosa, Alcoholic hepatitis, Diabetes, Sjogren's syndrome, Multiple Sclerosis, Ankylosing spondylitis, Membranous glomerulopathy, Discogenic pain, Systemic Lupus Erythematosus; Disease involving angiogenesis including cancer, psoriasis, rheumatoid arthritis; Psychological disorders including bipolar disease, schizophrenia, mania, depression and dementia; Cardiovascular Diseases including Heart failure, restenosis and arteriosclerosis; Fibrotic diseases including liver fibrosis, cystic fibrosis and angiofibroma; Infectious diseases including Fungal infections, such as Candida Albicans, Bacterial infections, Viral infections, such as Herpes Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.

131. (Currently Amended) A method for inhibiting cell proliferation including administration of an effective amount of a compound according to claim [[80]] 81.

132. (Currently Amended) A method of treatment of a neurodegenerative disorder in a patient including administration of a therapeutically effective amount of a compound according to claim [[80]] 81 to the patient.

133. (Previously Presented) A method according to claim 132 wherein the neurodegenerative disorder is Huntington's Disease.

134. (Currently Amended) A method of treatment of an inflammatory disease and/or immune system disorder in a patient including administration of a therapeutically effective amount of a compound according to claim [[80]] 81 to the patient.

135. (Previously Presented) A method according to claim 134 wherein the inflammatory disease and/or immune system disorder is rheumatoid arthritis.

136. (Previously Presented) A method according to claim 134 wherein the inflammatory disease and/or immune system disorder is systemic lupus erythematosus.

137. (Currently amended) A method of treatment of a proliferative disorder in patient including administration of a therapeutically effective amount of a compound according to claim [[80]] 81 to the patient.

138. (Currently Amended) A method of treatment of cancer in patient including administration of a therapeutically effective amount of a compound according to claim [[80]] 81 to the patient.

139. (Previously Presented) A method according to claim 138 wherein the cancer is a hematologic malignancy.

140. (Previously Presented) A method according to claim 139 wherein the hematologic malignancy is selected from the group consisting of B-cell lymphoma, T-cell lymphoma and leukemia.

141. (Previously Presented) A method according to claim 138 wherein the cancer is a solid tumor.

142. (Previously Presented) A method according to claim 141 wherein the solid tumor is selected from the group consisting of breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.

143. (Currently Amended) A method of induction of apoptosis of a cell including contacting the cell with an effective amount of a compound according to claim [[80]] 81.

144. (Previously Presented) A method according to claim 124 wherein the histone deacetylase is HDAC1.

145. (Previously Presented) A method according to claim 124 wherein the histone deacetylase is HDAC8.

146. (Previously Presented) A method according to claim 128 wherein the disorder is selected from the group consisting of Proliferative disorders (e.g. cancer); Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesia, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Progressive supranuclear palsy, Pick's disease, Intracerebral haemorrhage, Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration, Rubeotic glaucoma, Interstitial keratitis, Diabetic retinopathy; Inflammatory diseases and/or Immune system disorders including Rheumatoid Arthritis (RA), Osteoarthritis, Juvenile chronic arthritis, Graft versus Host disease, Psoriasis, Asthma, Spondyloarthropathy, Crohn's Disease, Inflammatory bowel disease, Colitis Ulcerosa, Alcoholic hepatitis, Diabetes, Sjogren's syndrome, Multiple Sclerosis, Ankylosing

spondylitis, Membranous glomerulopathy, Discogenic pain, Systemic Lupus Erythematosus; Disease involving angiogenesis including cancer, psoriasis, rheumatoid arthritis; Psychological disorders including bipolar disease, schizophrenia, mania, depression and dementia; Cardiovascular Diseases including Heart failure, restenosis and arteriosclerosis; Fibrotic diseases including liver fibrosis, cystic fibrosis and angiofibroma; Infectious diseases including Fungal infections, such as Candida Albicans, Bacterial infections, Viral infections, such as Herpes Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.

147. (Previously Presented) A method according to claim 129 wherein the disorder is selected from the group consisting of Proliferative disorders (e.g. cancer); Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesia, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Progressive supranuclear palsy, Pick's disease, Intracerebral haemorrhage, Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration, Rubeotic glaucoma, Interstitial keratitis, Diabetic retinopathy; Inflammatory diseases and/or Immune system disorders including Rheumatoid Arthritis (RA), Osteoarthritis, Juvenile chronic arthritis, Graft versus Host disease, Psoriasis, Asthma, Spondyloarthropathy, Crohn's Disease, Inflammatory bowel disease, Colitis Ulcerosa, Alcoholic hepatitis, Diabetes, Sjogren's syndrome, Multiple Sclerosis, Ankylosing spondylitis, Membranous glomerulopathy, Discogenic pain, Systemic Lupus Erythematosus; Disease involving angiogenesis including cancer, psoriasis, rheumatoid arthritis; Psychological disorders including bipolar disease, schizophrenia, mania, depression and dementia; Cardiovascular Diseases including Heart failure, restenosis and arteriosclerosis; Fibrotic diseases including liver fibrosis, cystic fibrosis and angiofibroma; Infectious diseases including Fungal infections, such as Candida Albicans, Bacterial infections, Viral infections, such as Herpes

Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.